|
OMIM |
Link |
Information gain |
01 |
|
IDDM
|
[NCBI]
|
0.0135465
|
|
|
VRNI
|
[NCBI]
|
0.00391555
|
|
|
IGAN1
|
[NCBI]
|
0.00333079
|
|
|
MYMY1
|
[NCBI]
|
0.00280491
|
|
|
hodgkin disease, x-linked pseudoautosomal
|
[NCBI]
|
0.00280491
|
|
|
IDDM13
|
[NCBI]
|
0.00269926
|
|
|
PSORS3
|
[NCBI]
|
0.00269926
|
|
|
HFE
|
[NCBI]
|
0.00222591
|
|
|
IDDM15
|
[NCBI]
|
0.00198909
|
|
|
APS2
|
[NCBI]
|
0.00195487
|
|
|
WM1
|
[NCBI]
|
0.00182197
|
|
|
behcet syndrome
|
[NCBI]
|
0.00181895
|
|
|
hla-d histocompatibility type
|
[NCBI]
|
0.00149177
|
|
|
apnea, obstructive sleep
|
[NCBI]
|
0.00143198
|
|
|
systemic lupus erythematosus, susceptibility to, 7
|
[NCBI]
|
0.00134792
|
|
|
LAP
|
[NCBI]
|
0.00134792
|
|
|
narcolepsy 2
|
[NCBI]
|
0.00134792
|
|
|
OD
|
[NCBI]
|
0.00134792
|
|
|
myositis
|
[NCBI]
|
0.00134792
|
|
|
laryngeal abductor paralysis
|
[NCBI]
|
0.00134792
|
|
|
hodgkin disease, y-linked pseudoautosomal
|
[NCBI]
|
0.00134792
|
|
|
mycobacterium tuberculosis, susceptibility to, 1
|
[NCBI]
|
0.00134792
|
|
|
panbronchiolitis, diffuse
|
[NCBI]
|
0.0011716
|
|
|
CF
|
[NCBI]
|
0.00115208
|
|
|
CMM
|
[NCBI]
|
0.00109467
|
|
|
myoclonic epilepsy, juvenile, 3
|
[NCBI]
|
0.00106492
|
|
|
IDDM4
|
[NCBI]
|
0.00106492
|
|
|
PSORS2
|
[NCBI]
|
0.00106492
|
|
|
IDDM7
|
[NCBI]
|
0.00106492
|
|
|
IGAD1
|
[NCBI]
|
0.000992998
|
|
|
adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency
|
[NCBI]
|
0.000991308
|
|
|
HLA-A
|
[NCBI]
|
0.000987543
|
|
|
MAFD1
|
[NCBI]
|
0.000849977
|
|
|
leprosy, susceptibility to, 1
|
[NCBI]
|
0.000835353
|
|
|
syringomyelia, isolated
|
[NCBI]
|
0.000835353
|
|
|
peyronie disease
|
[NCBI]
|
0.000835353
|
|
|
molar i reinclusion
|
[NCBI]
|
0.000835353
|
|
|
systemic lupus erythematosus, susceptibility to, 6
|
[NCBI]
|
0.000835353
|
|
|
AKE
|
[NCBI]
|
0.000835353
|
|
|
psoriasis susceptibility 6
|
[NCBI]
|
0.000835353
|
|
|
ASD1
|
[NCBI]
|
0.000835353
|
|
|
EC1
|
[NCBI]
|
0.000835353
|
|
|
CELIAC2
|
[NCBI]
|
0.000835353
|
|
|
graves disease, susceptibility to, 2
|
[NCBI]
|
0.000835353
|
|
|
IDDM8
|
[NCBI]
|
0.000835353
|
|
|
IDDM6
|
[NCBI]
|
0.000835353
|
|
|
alopecia areata 1
|
[NCBI]
|
0.00076474
|
|
|
SCA1
|
[NCBI]
|
0.000764315
|
|
|
SPDA1
|
[NCBI]
|
0.000668972
|
|
|
CD
|
[NCBI]
|
0.000660581
|
|
|
acroosteolysis with osteoporosis and changes in skull and mandible
|
[NCBI]
|
0.000648567
|
|
|
IDDM3
|
[NCBI]
|
0.000648567
|
|
|
psoriasis susceptibility 8
|
[NCBI]
|
0.000648567
|
|
|
autoimmune thyroid disease, susceptibility to, 2
|
[NCBI]
|
0.000648567
|
|
|
IDDM18
|
[NCBI]
|
0.000648567
|
|
|
IDDM11
|
[NCBI]
|
0.000648567
|
|
|
RA
|
[NCBI]
|
0.00063898
|
|
|
PCOS1
|
[NCBI]
|
0.00060228
|
|
|
IBD3
|
[NCBI]
|
0.000531031
|
|
|
nasopharyngeal carcinoma 1
|
[NCBI]
|
0.000531031
|
|
|
complement component 2 deficiency
|
[NCBI]
|
0.000517897
|
|
|
scleroderma, familial progressive
|
[NCBI]
|
0.000499448
|
|
|
HLA-DRA
|
[NCBI]
|
0.000479613
|
|
|
HLA-G
|
[NCBI]
|
0.000446649
|
|
|
chiari malformation type i
|
[NCBI]
|
0.000446386
|
|
|
gastroesophageal reflux
|
[NCBI]
|
0.000446386
|
|
|
MRD
|
[NCBI]
|
0.000446386
|
|
|
takayasu arteritis
|
[NCBI]
|
0.000442763
|
|
|
autoimmune disease
|
[NCBI]
|
0.000407173
|
|
|
C4A
|
[NCBI]
|
0.000405661
|
|
|
bare lymphocyte syndrome, type ii
|
[NCBI]
|
0.000394654
|
|
|
MVP
|
[NCBI]
|
0.000381114
|
|
|
C4B
|
[NCBI]
|
0.000378927
|
|
|
diabetes mellitus, insulin-dependent, 2
|
[NCBI]
|
0.000358001
|
|
|
AD
|
[NCBI]
|
0.000355313
|
|
|
lichen planus, familial
|
[NCBI]
|
0.000339803
|
|
|
hodgkin lymphoma
|
[NCBI]
|
0.000337397
|
|
|
nasopharyngeal carcinoma
|
[NCBI]
|
0.000310085
|
|
|
immunodeficiency, partial combined, with absence of hla determinants and beta-2-microglobulin from lymphocytes
|
[NCBI]
|
0.000297352
|
|
|
neutrophilic dermatosis, acute febrile
|
[NCBI]
|
0.000285275
|
|
|
CLL
|
[NCBI]
|
0.000259925
|
|
|
HFE3
|
[NCBI]
|
0.000257109
|
|
|
CFB
|
[NCBI]
|
0.000251449
|
|
|
neural tube defects
|
[NCBI]
|
0.000250315
|
|
|
IGES
|
[NCBI]
|
0.00024871
|
|
|
HFE4
|
[NCBI]
|
0.000234282
|
|
|
CRC
|
[NCBI]
|
0.000221528
|
|
|
PSORS1
|
[NCBI]
|
0.000219825
|
|
|
omenn syndrome
|
[NCBI]
|
0.000216326
|
|
|
OFC1
|
[NCBI]
|
0.000209278
|
|
|
allergic bronchopulmonary aspergillosis
|
[NCBI]
|
0.000198207
|
|
|
ST3
|
[NCBI]
|
0.000190366
|
|
|
IS
|
[NCBI]
|
0.000189599
|
|
|
MG
|
[NCBI]
|
0.000185397
|
|
|
HLA-B
|
[NCBI]
|
0.000184875
|
|
|
iron overload in africa
|
[NCBI]
|
0.000178224
|
|
|
SCA2
|
[NCBI]
|
0.000162613
|
|
|
HLA-E
|
[NCBI]
|
0.000160902
|
|
|
MS
|
[NCBI]
|
0.000156565
|
|
|
PGM3
|
[NCBI]
|
0.000156149
|
|
|
hepatitis b vaccine, response to
|
[NCBI]
|
0.000154988
|
|
|
sjogren syndrome
|
[NCBI]
|
0.000146016
|
|
|
GLO1
|
[NCBI]
|
0.000142839
|
|
|
NRCLP1
|
[NCBI]
|
0.00014193
|
|
|
synovitis, granulomatous, with uveitis and cranial neuropathies
|
[NCBI]
|
0.000140275
|
|
|
MDD
|
[NCBI]
|
0.000138558
|
|
|
rheumatic fever-related antigen
|
[NCBI]
|
0.000135617
|
|
|
pneumothorax, primary spontaneous
|
[NCBI]
|
0.000135617
|
|
|
PDB1
|
[NCBI]
|
0.000135617
|
|
|
porphyria cutanea tarda
|
[NCBI]
|
0.000129855
|
|
|
PDB
|
[NCBI]
|
0.000116973
|
|
|
HLA-C
|
[NCBI]
|
0.000114625
|
|
|
CCAL2
|
[NCBI]
|
0.000113235
|
|
|
sacral defect with anterior meningocele
|
[NCBI]
|
0.000112361
|
|
|
hashimoto thyroiditis
|
[NCBI]
|
0.000111482
|
|
|
adrenal hyperplasia, congenital, due to 17-alpha-hydroxylase deficiency
|
[NCBI]
|
0.000109723
|
|
|
adrenal hyperplasia, congenital, due to steroid 11-beta-hydroxylase deficiency
|
[NCBI]
|
0.000106412
|
|
|
HYR
|
[NCBI]
|
0.000104253
|
|
|
ascaris lumbricoides infection, susceptibility to
|
[NCBI]
|
9.90898e-05
|
|
|
neural tube defects, x-linked
|
[NCBI]
|
9.90898e-05
|
|
|
hypersensitivity pneumonitis, familial
|
[NCBI]
|
9.90898e-05
|
|
|
arteritis, familial granulomatous, with juvenile polyarthritis
|
[NCBI]
|
9.90898e-05
|
|
|
chondrocalcinosis due to apatite crystal deposition
|
[NCBI]
|
9.90898e-05
|
|
|
MAPTL
|
[NCBI]
|
9.90898e-05
|
|
|
erythema nodosum, familial
|
[NCBI]
|
9.90898e-05
|
|
|
eosinophilic fasciitis
|
[NCBI]
|
9.90898e-05
|
|
|
PUPPP
|
[NCBI]
|
9.90898e-05
|
|
|
APC
|
[NCBI]
|
9.74952e-05
|
|
|
amyloidosis, familial visceral
|
[NCBI]
|
9.74665e-05
|
|
|
TINU
|
[NCBI]
|
9.74665e-05
|
|
|
CJD
|
[NCBI]
|
9.65302e-05
|
|
|
HLA-DRB1
|
[NCBI]
|
9.19113e-05
|
|
|
SLE
|
[NCBI]
|
9.04858e-05
|
|
|
F13A1
|
[NCBI]
|
8.93661e-05
|
|
|
APS1
|
[NCBI]
|
8.70874e-05
|
|
|
malaria, susceptibility to
|
[NCBI]
|
8.52431e-05
|
|
|
HLA-MT
|
[NCBI]
|
8.44851e-05
|
|
|
THC2
|
[NCBI]
|
8.20189e-05
|
|
|
graves disease
|
[NCBI]
|
8.10307e-05
|
|
|
HLA-DPA1
|
[NCBI]
|
7.92087e-05
|
|
|
human immunodeficiency virus type 1, susceptibility to
|
[NCBI]
|
7.90456e-05
|
|
|
VEGF
|
[NCBI]
|
7.86266e-05
|
|
|
HLA-F
|
[NCBI]
|
7.85237e-05
|
|
|
SKIV2L
|
[NCBI]
|
7.85237e-05
|
|
|
ICP
|
[NCBI]
|
7.79578e-05
|
|
|
EGF
|
[NCBI]
|
7.7876e-05
|
|
|
CMH
|
[NCBI]
|
7.32781e-05
|
|
|
hemophagocytic lymphohistiocytosis, familial, 1
|
[NCBI]
|
7.27708e-05
|
|
|
complement component 8 deficiency, type i
|
[NCBI]
|
7.2049e-05
|
|
|
leprosy, susceptibility to, 2
|
[NCBI]
|
6.7795e-05
|
|
|
persistent polyclonal b-cell lymphocytosis
|
[NCBI]
|
6.7795e-05
|
|
|
steatocystoma multiplex
|
[NCBI]
|
6.7795e-05
|
|
|
hypotrichosis simplex of scalp
|
[NCBI]
|
6.7795e-05
|
|
|
gonadal agenesis
|
[NCBI]
|
6.7795e-05
|
|
|
S CHOICE OF
|
[NCBI]
|
6.7795e-05
|
|
|
t-cell subgroups, non-hla-linked
|
[NCBI]
|
6.7795e-05
|
|
|
epstein-barr virus, susceptibility to chronic infection by
|
[NCBI]
|
6.7795e-05
|
|
|
nephropathy with pretibial epidermolysis bullosa and deafness
|
[NCBI]
|
6.7795e-05
|
|
|
immunodeficiency, x-linked, with deficiency of 115,000 dalton surface glycoprotein
|
[NCBI]
|
6.7795e-05
|
|
|
fibrosclerosis, multifocal
|
[NCBI]
|
6.7795e-05
|
|
|
aHUS
|
[NCBI]
|
6.69817e-05
|
|
|
complement component 6 deficiency
|
[NCBI]
|
6.25059e-05
|
|
|
complement component 7 deficiency
|
[NCBI]
|
5.98574e-05
|
|
|
TNF
|
[NCBI]
|
5.69697e-05
|
|
|
CELIAC4
|
[NCBI]
|
5.61675e-05
|
|
|
erythroleukemia, familial
|
[NCBI]
|
5.61675e-05
|
|
|
PLT1
|
[NCBI]
|
5.61675e-05
|
|
|
buerger disease
|
[NCBI]
|
5.61675e-05
|
|
|
pyogenic sterile arthritis, pyoderma gangrenosum, and acne
|
[NCBI]
|
5.61675e-05
|
|
|
RCM1
|
[NCBI]
|
5.61675e-05
|
|
|
surface antigen, glycoprotein 75
|
[NCBI]
|
5.61675e-05
|
|
|
cirrhosis, familial
|
[NCBI]
|
5.61675e-05
|
|
|
CSCI
|
[NCBI]
|
5.61675e-05
|
|
|
pulmonary fibrosis, idiopathic
|
[NCBI]
|
5.5375e-05
|
|
|
CPI
|
[NCBI]
|
5.45217e-05
|
|
|
RNF39
|
[NCBI]
|
5.41243e-05
|
|
|
ZNRD1
|
[NCBI]
|
5.41243e-05
|
|
|
thrombocytopenic purpura, autoimmune
|
[NCBI]
|
5.16754e-05
|
|
|
PWS
|
[NCBI]
|
5.03104e-05
|
|
|
AN1
|
[NCBI]
|
4.87206e-05
|
|
|
bare lymphocyte syndrome, type i
|
[NCBI]
|
4.87206e-05
|
|
|
raph blood group system
|
[NCBI]
|
4.87206e-05
|
|
|
vitiligo
|
[NCBI]
|
4.87206e-05
|
|
|
HAE
|
[NCBI]
|
4.84078e-05
|
|
|
CMD1A
|
[NCBI]
|
4.78451e-05
|
|
|
STK19
|
[NCBI]
|
4.63565e-05
|
|
|
KLRD1
|
[NCBI]
|
4.63565e-05
|
|
|
B2M
|
[NCBI]
|
4.4661e-05
|
|
|
HLA-DQA1
|
[NCBI]
|
4.41069e-05
|
|
|
BL
|
[NCBI]
|
4.40243e-05
|
|
|
KIR2DL2
|
[NCBI]
|
4.39384e-05
|
|
|
minor histocompatibility antigen ha-1
|
[NCBI]
|
4.39384e-05
|
|
|
mast cell disease
|
[NCBI]
|
4.3259e-05
|
|
|
OPLL
|
[NCBI]
|
4.3259e-05
|
|
|
GBS
|
[NCBI]
|
4.3259e-05
|
|
|
IDDM10
|
[NCBI]
|
4.3259e-05
|
|
|
IDDM5
|
[NCBI]
|
4.3259e-05
|
|
|
IDDM12
|
[NCBI]
|
4.3259e-05
|
|
|
IBD1
|
[NCBI]
|
4.27834e-05
|
|
|
SLC40A1
|
[NCBI]
|
4.25893e-05
|
|
|
ICAM1
|
[NCBI]
|
4.07761e-05
|
|
|
LSA
|
[NCBI]
|
4.03557e-05
|
|
|
LILRB1
|
[NCBI]
|
4.03255e-05
|
|
|
ragweed sensitivity
|
[NCBI]
|
3.89669e-05
|
|
|
AITD3
|
[NCBI]
|
3.89669e-05
|
|
|
kawasaki disease
|
[NCBI]
|
3.89669e-05
|
|
|
periodontitis, aggressive, 1
|
[NCBI]
|
3.89669e-05
|
|
|
RFXAP
|
[NCBI]
|
3.89e-05
|
|
|
LAG5
|
[NCBI]
|
3.89e-05
|
|
|
KLK3
|
[NCBI]
|
3.71622e-05
|
|
|
IGER
|
[NCBI]
|
3.66035e-05
|
|
|
IL2
|
[NCBI]
|
3.63888e-05
|
|
|
HS
|
[NCBI]
|
3.57425e-05
|
|
|
cirrhosis, familial
|
[NCBI]
|
3.54475e-05
|
|
|
hemochromatosis, neonatal
|
[NCBI]
|
3.54475e-05
|
|
|
hyperthyroidism, nonautoimmune
|
[NCBI]
|
3.54475e-05
|
|
|
GLYS1
|
[NCBI]
|
3.54475e-05
|
|
|
PRL
|
[NCBI]
|
3.52693e-05
|
|
|
WAS
|
[NCBI]
|
3.41744e-05
|
|
|
KIR2DL1
|
[NCBI]
|
3.37487e-05
|
|
|
PG
|
[NCBI]
|
3.35133e-05
|
|
|
PBC
|
[NCBI]
|
3.24772e-05
|
|
|
myasthenic syndrome, congenital, fast-channel
|
[NCBI]
|
3.24772e-05
|
|
|
TAP1
|
[NCBI]
|
3.22398e-05
|
|
|
hairy palms and soles
|
[NCBI]
|
3.21643e-05
|
|
|
narcolepsy candidate region gene 1a
|
[NCBI]
|
3.21643e-05
|
|
|
minor histocompatibility antigen hb-1
|
[NCBI]
|
3.21643e-05
|
|
|
SLC17A2
|
[NCBI]
|
3.21643e-05
|
|
|
EGFR
|
[NCBI]
|
3.16275e-05
|
|
|
PGK2
|
[NCBI]
|
3.15608e-05
|
|
|
CRH
|
[NCBI]
|
3.13972e-05
|
|
|
MYB
|
[NCBI]
|
3.03242e-05
|
|
|
hepatitis b virus, susceptibility to
|
[NCBI]
|
2.99177e-05
|
|
|
complement component 5 deficiency
|
[NCBI]
|
2.99177e-05
|
|
|
severe cutaneous adverse reaction, susceptibility to
|
[NCBI]
|
2.99177e-05
|
|
|
pemphigus vulgaris, familial
|
[NCBI]
|
2.99177e-05
|
|
|
pancreatic agenesis, congenital
|
[NCBI]
|
2.99177e-05
|
|
|
RP
|
[NCBI]
|
2.90841e-05
|
|
|
G6PC2
|
[NCBI]
|
2.8226e-05
|
|
|
sarcoidosis
|
[NCBI]
|
2.76768e-05
|
|
|
hyperferritinemia-cataract syndrome
|
[NCBI]
|
2.76768e-05
|
|
|
myeloma, multiple
|
[NCBI]
|
2.76768e-05
|
|
|
LQT1
|
[NCBI]
|
2.76488e-05
|
|
|
severe combined immunodeficiency with sensitivity to ionizing radiation
|
[NCBI]
|
2.56906e-05
|
|
|
TH
|
[NCBI]
|
2.56658e-05
|
|
|
breast cancer
|
[NCBI]
|
2.52406e-05
|
|
|
VARS
|
[NCBI]
|
2.4754e-05
|
|
|
DOM3Z
|
[NCBI]
|
2.4754e-05
|
|
|
HLA8
|
[NCBI]
|
2.4754e-05
|
|
|
C6ORF27
|
[NCBI]
|
2.4754e-05
|
|
|
ZFAT1
|
[NCBI]
|
2.4754e-05
|
|
|
SLC17A3
|
[NCBI]
|
2.4754e-05
|
|
|
amyloidosis, primary cutaneous
|
[NCBI]
|
2.39125e-05
|
|
|
MODY1
|
[NCBI]
|
2.39125e-05
|
|
|
EFE
|
[NCBI]
|
2.39125e-05
|
|
|
MPO
|
[NCBI]
|
2.38324e-05
|
|
|
DYX2
|
[NCBI]
|
2.23077e-05
|
|
|
UBD
|
[NCBI]
|
2.19652e-05
|
|
|
HSPA1B
|
[NCBI]
|
2.19652e-05
|
|
|
MLN
|
[NCBI]
|
2.19652e-05
|
|
|
IGLP1
|
[NCBI]
|
2.19652e-05
|
|
|
HLA-DNA
|
[NCBI]
|
2.19652e-05
|
|
|
IHG
|
[NCBI]
|
2.19652e-05
|
|
|
TFR2
|
[NCBI]
|
2.13226e-05
|
|
|
leprosy, susceptibility to
|
[NCBI]
|
2.08495e-05
|
|
|
JH
|
[NCBI]
|
2.08495e-05
|
|
|
EPO
|
[NCBI]
|
2.05155e-05
|
|
|
HSD17B8
|
[NCBI]
|
2.01588e-05
|
|
|
LILRB3
|
[NCBI]
|
2.01588e-05
|
|
|
LFA3
|
[NCBI]
|
2.01588e-05
|
|
|
PSMB8
|
[NCBI]
|
2.01588e-05
|
|
|
antigen defined by monoclonal antibody f10.44.2
|
[NCBI]
|
2.01588e-05
|
|
|
CD5
|
[NCBI]
|
2.01588e-05
|
|
|
PRAME
|
[NCBI]
|
2.01588e-05
|
|
|
LILRA3
|
[NCBI]
|
2.01588e-05
|
|
|
IK
|
[NCBI]
|
2.01588e-05
|
|
|
severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-negative, nk cell-positive
|
[NCBI]
|
1.95168e-05
|
|
|
platelet glycoprotein iv deficiency
|
[NCBI]
|
1.95168e-05
|
|
|
HGF
|
[NCBI]
|
1.93194e-05
|
|
|
PPP1R11
|
[NCBI]
|
1.88189e-05
|
|
|
alkaline phosphatase, elevated serum
|
[NCBI]
|
1.88189e-05
|
|
|
SART1
|
[NCBI]
|
1.88189e-05
|
|
|
KLRC2
|
[NCBI]
|
1.88189e-05
|
|
|
minor histocompatibility antigen ha-2
|
[NCBI]
|
1.88189e-05
|
|
|
LILRB2
|
[NCBI]
|
1.88189e-05
|
|
|
SLC39A7
|
[NCBI]
|
1.88189e-05
|
|
|
17-@beta hydroxysteroid dehydrogenase iii deficiency
|
[NCBI]
|
1.82929e-05
|
|
|
testicular tumors
|
[NCBI]
|
1.82929e-05
|
|
|
SLC11A1
|
[NCBI]
|
1.78144e-05
|
|
|
KIR2DL3
|
[NCBI]
|
1.77539e-05
|
|
|
CTSH
|
[NCBI]
|
1.77539e-05
|
|
|
HSPA1L
|
[NCBI]
|
1.77539e-05
|
|
|
TCP1
|
[NCBI]
|
1.77539e-05
|
|
|
progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant, 1
|
[NCBI]
|
1.71641e-05
|
|
|
PPH1
|
[NCBI]
|
1.71641e-05
|
|
|
neuraminidase deficiency
|
[NCBI]
|
1.70509e-05
|
|
|
ACAT2
|
[NCBI]
|
1.68704e-05
|
|
|
HLA-DPB1
|
[NCBI]
|
1.68704e-05
|
|
|
HGPS
|
[NCBI]
|
1.65404e-05
|
|
|
complement factor h deficiency
|
[NCBI]
|
1.61193e-05
|
|
|
SCCMS
|
[NCBI]
|
1.61193e-05
|
|
|
OPTB1
|
[NCBI]
|
1.61193e-05
|
|
|
pituitary dwarfism iii
|
[NCBI]
|
1.61193e-05
|
|
|
KLRC1
|
[NCBI]
|
1.6116e-05
|
|
|
PSTPIP1
|
[NCBI]
|
1.6116e-05
|
|
|
HMI
|
[NCBI]
|
1.6116e-05
|
|
|
TAPBP
|
[NCBI]
|
1.6116e-05
|
|
|
IFNGR2
|
[NCBI]
|
1.6116e-05
|
|
|
SCA17
|
[NCBI]
|
1.51491e-05
|
|
|
blood group, p system
|
[NCBI]
|
1.51491e-05
|
|
|
IL10
|
[NCBI]
|
1.50407e-05
|
|
|
AZGP1
|
[NCBI]
|
1.48751e-05
|
|
|
TMSB4X
|
[NCBI]
|
1.48751e-05
|
|
|
SLC11A2
|
[NCBI]
|
1.43544e-05
|
|
|
complement component c1r deficiency
|
[NCBI]
|
1.43519e-05
|
|
|
KAL2
|
[NCBI]
|
1.42456e-05
|
|
|
BCGF
|
[NCBI]
|
1.41892e-05
|
|
|
VHL
|
[NCBI]
|
1.41892e-05
|
|
|
MEN1
|
[NCBI]
|
1.40308e-05
|
|
|
AL-A1
|
[NCBI]
|
1.38776e-05
|
|
|
KIR3DL1
|
[NCBI]
|
1.3444e-05
|
|
|
alkaptonuria
|
[NCBI]
|
1.34022e-05
|
|
|
MEN2A
|
[NCBI]
|
1.33347e-05
|
|
|
HBFQTL2
|
[NCBI]
|
1.31572e-05
|
|
|
AIRE
|
[NCBI]
|
1.31286e-05
|
|
|
ART4
|
[NCBI]
|
1.26752e-05
|
|
|
LFS1
|
[NCBI]
|
1.26131e-05
|
|
|
glycogen storage disease iv
|
[NCBI]
|
1.26131e-05
|
|
|
HEPH
|
[NCBI]
|
1.23312e-05
|
|
|
TUBB
|
[NCBI]
|
1.23312e-05
|
|
|
C4BPA
|
[NCBI]
|
1.23312e-05
|
|
|
niemann-pick disease, type b
|
[NCBI]
|
1.18734e-05
|
|
|
GTS
|
[NCBI]
|
1.18385e-05
|
|
|
C7
|
[NCBI]
|
1.17075e-05
|
|
|
DDR1
|
[NCBI]
|
1.17075e-05
|
|
|
prekallikrein deficiency
|
[NCBI]
|
1.17075e-05
|
|
|
MME
|
[NCBI]
|
1.1423e-05
|
|
|
DAR
|
[NCBI]
|
1.11787e-05
|
|
|
NEU1
|
[NCBI]
|
1.08996e-05
|
|
|
USF2
|
[NCBI]
|
1.08996e-05
|
|
|
C9
|
[NCBI]
|
1.06577e-05
|
|
|
HAMP
|
[NCBI]
|
1.06577e-05
|
|
|
CDSN
|
[NCBI]
|
1.06577e-05
|
|
|
melanoma, uveal
|
[NCBI]
|
1.05254e-05
|
|
|
F3
|
[NCBI]
|
1.04579e-05
|
|
|
CHRNA1
|
[NCBI]
|
1.04274e-05
|
|
|
HLA-DQB1
|
[NCBI]
|
1.04274e-05
|
|
|
TNXB
|
[NCBI]
|
1.04274e-05
|
|
|
HSPA1A
|
[NCBI]
|
9.99771e-06
|
|
|
IFNA1
|
[NCBI]
|
9.52744e-06
|
|
|
cerebrotendinous xanthomatosis
|
[NCBI]
|
9.32993e-06
|
|
|
OPA1
|
[NCBI]
|
9.32993e-06
|
|
|
glycogen storage disease iii
|
[NCBI]
|
9.32993e-06
|
|
|
MUT
|
[NCBI]
|
9.24056e-06
|
|
|
IFNGR1
|
[NCBI]
|
9.06907e-06
|
|
|
ATXN1
|
[NCBI]
|
8.90373e-06
|
|
|
leber optic atrophy
|
[NCBI]
|
8.84187e-06
|
|
|
CMT1B
|
[NCBI]
|
8.78222e-06
|
|
|
thrombasthenia of glanzmann and naegeli
|
[NCBI]
|
8.4666e-06
|
|
|
PPOX
|
[NCBI]
|
8.29656e-06
|
|
|
CFI
|
[NCBI]
|
8.29656e-06
|
|
|
XPA
|
[NCBI]
|
8.26468e-06
|
|
|
POU1F1
|
[NCBI]
|
8.02116e-06
|
|
|
LTA
|
[NCBI]
|
7.88961e-06
|
|
|
anemia, sideroblastic, x-linked
|
[NCBI]
|
7.88961e-06
|
|
|
NOD2
|
[NCBI]
|
7.88961e-06
|
|
|
ABO
|
[NCBI]
|
7.63775e-06
|
|
|
KAL1
|
[NCBI]
|
7.63775e-06
|
|
|
CHS
|
[NCBI]
|
7.5458e-06
|
|
|
AFP
|
[NCBI]
|
7.48508e-06
|
|
|
MCP
|
[NCBI]
|
7.43316e-06
|
|
|
RCC1
|
[NCBI]
|
7.31198e-06
|
|
|
AR
|
[NCBI]
|
7.17836e-06
|
|
|
LIF
|
[NCBI]
|
7.17397e-06
|
|
|
CTLA4
|
[NCBI]
|
7.17397e-06
|
|
|
polycystic kidneys
|
[NCBI]
|
7.00873e-06
|
|
|
CVID
|
[NCBI]
|
6.91973e-06
|
|
|
PCD
|
[NCBI]
|
6.86714e-06
|
|
|
CEACAM5
|
[NCBI]
|
6.81942e-06
|
|
|
transcobalamin ii deficiency
|
[NCBI]
|
6.75567e-06
|
|
|
MODY
|
[NCBI]
|
6.57062e-06
|
|
|
IFNG
|
[NCBI]
|
6.46729e-06
|
|
|
LWD
|
[NCBI]
|
6.45752e-06
|
|
|
IGHG1
|
[NCBI]
|
6.19785e-06
|
|
|
TFRC
|
[NCBI]
|
5.86452e-06
|
|
|
severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-negative, nk cell-negative, due to adenosine deaminase deficiency
|
[NCBI]
|
5.71385e-06
|
|
|
PGK1
|
[NCBI]
|
5.63176e-06
|
|
|
SPTA1
|
[NCBI]
|
5.41218e-06
|
|
|
MTND4
|
[NCBI]
|
5.41218e-06
|
|
|
DMD
|
[NCBI]
|
5.14665e-06
|
|
|
ITGB3
|
[NCBI]
|
5.13785e-06
|
|
|
DSG3
|
[NCBI]
|
5.13785e-06
|
|
|
MBP
|
[NCBI]
|
5.05543e-06
|
|
|
HIGM1
|
[NCBI]
|
4.99836e-06
|
|
|
periodic fever, familial, autosomal dominant
|
[NCBI]
|
4.99836e-06
|
|
|
HBD
|
[NCBI]
|
4.82117e-06
|
|
|
CD36
|
[NCBI]
|
4.58638e-06
|
|
|
FA
|
[NCBI]
|
4.52341e-06
|
|
|
BCPM
|
[NCBI]
|
4.37571e-06
|
|
|
TSHR
|
[NCBI]
|
4.31333e-06
|
|
|
MJD
|
[NCBI]
|
4.23221e-06
|
|
|
SRY
|
[NCBI]
|
4.10955e-06
|
|
|
BSG
|
[NCBI]
|
3.87119e-06
|
|
|
TNFRSF1A
|
[NCBI]
|
3.60663e-06
|
|
|
hurler syndrome
|
[NCBI]
|
3.55536e-06
|
|
|
PI
|
[NCBI]
|
3.51819e-06
|
|
|
HBB
|
[NCBI]
|
3.24186e-06
|
|
|
AT
|
[NCBI]
|
2.98643e-06
|
|
|
temporal arteritis
|
[NCBI]
|
2.93542e-06
|
|
|
hypophosphatemic rickets, x-linked dominant
|
[NCBI]
|
2.85446e-06
|
|
|
TF
|
[NCBI]
|
2.7525e-06
|
|
|
CTNS
|
[NCBI]
|
2.64459e-06
|
|
|
ESD
|
[NCBI]
|
2.64196e-06
|
|
|
CFH
|
[NCBI]
|
2.55304e-06
|
|
|
ARMD1
|
[NCBI]
|
2.44573e-06
|
|
|
MUC1
|
[NCBI]
|
2.4167e-06
|
|
|
CFTR
|
[NCBI]
|
2.31659e-06
|
|
|
INSR
|
[NCBI]
|
2.22614e-06
|
|
|
TNFSF6
|
[NCBI]
|
2.14362e-06
|
|
|
panencephalitis, subacute sclerosing
|
[NCBI]
|
2.11374e-06
|
|
|
GC
|
[NCBI]
|
1.78856e-06
|
|
|
TTR
|
[NCBI]
|
1.73414e-06
|
|
|
KSS
|
[NCBI]
|
1.64286e-06
|
|
|
CMT1A
|
[NCBI]
|
1.60127e-06
|
|
|
hemophilia a
|
[NCBI]
|
1.53549e-06
|
|
|
ADA
|
[NCBI]
|
1.52567e-06
|
|
|
ALD
|
[NCBI]
|
1.47414e-06
|
|
|
EV
|
[NCBI]
|
1.36433e-06
|
|
|
HEMB
|
[NCBI]
|
1.2357e-06
|
|
|
autism
|
[NCBI]
|
9.35908e-07
|
|
|
SCZD
|
[NCBI]
|
8.69582e-07
|
|
|
ALPS
|
[NCBI]
|
8.35715e-07
|
|
|
HP
|
[NCBI]
|
7.37339e-07
|
|
|
GRA
|
[NCBI]
|
6.83679e-07
|
|
|
gaucher disease, type i
|
[NCBI]
|
6.00503e-07
|
|
|
SOD2
|
[NCBI]
|
5.96661e-07
|
|
|
wilson disease
|
[NCBI]
|
5.26538e-07
|
|
|
TP53
|
[NCBI]
|
4.76534e-07
|
|
|
PDCD8
|
[NCBI]
|
3.3407e-07
|
|
|
asthma, susceptibility to
|
[NCBI]
|
3.28156e-07
|
|
|
EIG
|
[NCBI]
|
2.40636e-07
|
|
|
FRDA
|
[NCBI]
|
2.40636e-07
|
|
|
WRN
|
[NCBI]
|
2.25607e-07
|
|
|
porphyria variegata
|
[NCBI]
|
1.8215e-07
|
|
|
danubian endemic familial nephropathy
|
[NCBI]
|
1.8215e-07
|
|
|
FMF
|
[NCBI]
|
8.28798e-08
|
|
|
PGR
|
[NCBI]
|
7.63167e-08
|
|
|
CD
|
[NCBI]
|
5.98922e-08
|
|
|
HD
|
[NCBI]
|
5.92538e-08
|
|
|
MBL2
|
[NCBI]
|
4.97893e-08
|
|
|
STAT3
|
[NCBI]
|
1.22187e-08
|
|